Processa Pharmaceuticals (PCSA) Net Income (2012 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly Net Income came in at -$3.4 million in Q1 2026, down 19.15% YoY from -$4.2 million in Q1 2025, and up 8.77% on a QoQ basis from -$3.7 million in Q4 2025.
Processa Pharmaceuticals (PCSA) Net Income (2012 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 15 years of Net Income data on file, last reported at -$3.4 million in Q1 2026.
- Quarterly Net Income fell 19.15% year-over-year to -$3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$14.5 million (down 22.9% YoY) and the FY2025 annual result came in at $2.5 million, up 121.92% from the prior year.
- Net Income improved to -$3.4 million in Q1 2026, from -$3.7 million in the prior quarter.
- In the past five years, Net Income ranged from a high of -$2.3 million in Q3 2023 to a low of -$20.0 million in Q4 2023.
- A 5-year average of -$5.0 million and a median of -$3.5 million in 2024 frame the typical range for Net Income.
- Annual changes were most pronounced in 2022 — Net Income slumped 308.7% — and 2024, when it surged 87.54%.
- Tracing PCSA's Net Income over 5 years: stood at -$13.0 million in 2022, then sank by 54.04% to -$20.0 million in 2023, then surged by 87.54% to -$2.5 million in 2024, then tumbled by 48.28% to -$3.7 million in 2025, then grew by 8.77% to -$3.4 million in 2026.
- The last three Net Income figures came in at -$3.4 million (Q1 2026), -$3.7 million (Q4 2025), and -$3.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -355.03 Mn |
| 10 | Processa Pharmaceuticals | 5.93 Mn | 5.93 Mn | - | -2.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.38 Mn |
| Dec 31, 2025 | -3.70 Mn |
| Sep 30, 2025 | -3.49 Mn |
| Jun 30, 2025 | -3.95 Mn |
| Mar 31, 2025 | -2.83 Mn |
| Dec 31, 2024 | -2.50 Mn |
| Sep 30, 2024 | -3.48 Mn |
| Jun 30, 2024 | -3.01 Mn |
| Mar 31, 2024 | -3.03 Mn |
| Dec 31, 2023 | -20.04 Mn |
| Sep 30, 2023 | -2.27 Mn |
| Jun 30, 2023 | -2.61 Mn |
| Mar 31, 2023 | -4.02 Mn |
| Dec 31, 2022 | -13.01 Mn |
| Sep 30, 2022 | -6.02 Mn |
| Jun 30, 2022 | -5.16 Mn |
| Mar 31, 2022 | -3.23 Mn |
| Dec 31, 2021 | -3.18 Mn |
| Sep 30, 2021 | -2.99 Mn |
| Jun 30, 2021 | -3.16 Mn |